Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

New data show that TWYNSTA®, a once daily, single pill combination of the angiotensin II receptor blocker (ARB) telmisartan and the calcium channel blocker (CCB) amlodipine, leads to rapid and sustained blood pressure (BP) reductions that can bring most patients with previously uncontrolled hypertension on RAS inhibitor monotherapy to BP goal effectively within 4 weeks. 1

The results from the TEAMSTA Switch study, presented at the 22 nd Annual Scientific Meeting of the European Society of Hypertension (ESH) in London, show that TWYNSTA® delivers prompt BP control in the majority of patients with uncontrolled hypertension on RAS blocker monotherapy (i.e. angiotensin II receptor blockers, angiotensin-converting-enzyme inhibitors or direct renin inhibitors) and provides further confirmation of its excellent efficacy in controlling high blood pressure. 1

Despite decades of persistent efforts, in Europe the BP control of patients who suffer from hypertension is only approximately 30%. 2 “This study clearly shows that the combination of an ARB with a CCB is a highly effective way of optimising blood pressure control in the majority of people” said the lead author of TEAMSTA Switch, Professor Bryan Williams, Professor of Medicine at the University of Leicester.

Summary of the data:1,3,4

• Overall 53% patients reached office BP goal within 4 weeks and 67.6% within 12 weeks
• After 12 weeks, BP control rates ranged from 74.7-88% (depending on original monotherapy treatment) in patients receiving telmisartan 80mg/amlodipine 5mg and from 44.9-60.8% in patients who required uptitration to telmisartan 80mg/amlodipine 10mg at either week 4 or 6
• Uptitrated patients had a longer history of hypertension, a higher systolic blood pressure (SBP) at baseline and twice as often suffered from concomitant diabetes
• Using Home Blood Pressure Monitoring, 73.4% and 78.5% of patients reached the BP goal (<140/90 mmHg) after 4 and 12 weeks, respectively
• At baseline, 69% of patients had mild hypertension (140-159/90-99 mmHg) which decreased to 27.1% after 12 weeks of treatment
• At baseline, 26.5% of patients had moderate (160-179/100-109 mmHg) or severe hypertension (≥180/ 110mmHg) which decreased to 4.3% after 12 weeks of treatment
• TWYNSTA® showed a good safety profile and was well-tolerated in this patient population
• The most common adverse event was peripheral oedema which was experienced by 13.2% of patients, with 5.2% being considered clinically relevant by the treating physician

Professor Klaus Dugi, Corporate Senior Vice President Medicine at Boehringer Ingelheim, commented: “These latest findings add to a robust evidence base, confirming that TWYNSTA® is a valuable treatment option for patients with hypertension and is highly effective in helping patients who are uncontrolled to reach their BP goals.”

Previous data confirm TWYNSTA® delivers very effective BP reductions and high BP control rates in patients not controlled by amlodipine alone, as well as in those patients at greater risk of CV events, including patients with severe hypertension, Type 2 diabetes, and obesity and is safe and well tolerated. 5-9

TWYNSTA® contains telmisartan, the only ARB with a broad indication for CV prevention independent of blood pressure. 10

References

1. Williams B. et al. Efficacy of single-pill combination of telmisartan/amlodipine on blood pressure goal attainment in patients uncontrolled by RAS blocker monotherapy. TEAMSTA Switch Study. Abstract presented at European Society of Hypertension (ESH), April 2012
2. Pessina, AC, Ross, GP. Uncontrolled hypertension: highlights and perspectives from the European Society of Hypertension Satellite Symposium. Expert Rev. Cardiovasc. Ther 2011;9(12), 1515–1518
3. Data on file. Boehringer Ingelheim 2012
4. Williams B. et al. Efficacy of single-pill combination of telmisartan/amlodipine on Home Blood Pressure Measurement in patients uncontrolled by RAS blocker monotherapy. TEAMSTA Switch Study. Abstract presented at European Society of Hypertension (ESH), April 2012
5. White B et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1 -2 hypertension. Blood Press Monit 2010 Aug;15(4):205-12
6. Littlejohn J, et al. Results of treatment with telmisartan-amlodipine in Hypertensive Patients. J Clinl Hypertens 2009;11:4:207-213
7. Neutel JM. et al. Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA Severe HTN Study. Poster presentation at the European Society of Hypertension (ESH), June 2010.
8. Sharma AM. et al. Single-pill combination of telmisartan 80mg/amlodipine 10mg provides superior blood pressure reductions to amlodipine in added risk hypertensive patients. TEAMSTA Diabetes Study. Abstract presented at European Society of Hypertension (ESH), June 2011
9. Sharma AM. et al. Single-pill combination of telmisartan 80mg/amlodipine 10mg provides superior blood pressure reductions to amlodipine in added risk hypertensive patients: sub-analysis of the obese patients in the TEAMSTA Diabetes Study. Abstract presented at European Society of Hypertension (ESH), June 2011
10. Micardis SmPC